NorthCrest Asset Manangement’s TG Therapeutics TGTX Stock Holding History

NorthCrest Asset Manangement’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$908K	Buy	15,378 +1,071	+7%	+$43.8K	0.02%	400
2026 Q1	$480K	Buy	14,307 +316	+2%	+$9.42K	0.01%	493
2025 Q4	$418K	Buy	13,991 +74	+0.5%	+$2.42K	0.01%	594
2025 Q3	$508K	Buy	13,917 +5,527	+66%	+$182K	0.01%	488
2025 Q2	$308K	Sell	8,390 -6,520	-44%	-$243K	0.01%	513
2025 Q1	$588K	Buy	14,910 +20	+0.1%	+$673	0.02%	398
2024 Q4	$448K	Buy	+14,890	New	+$427K	0.01%	420

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

NorthCrest Asset Manangement's TGTX Position: Q2 2026 in Review

NorthCrest Asset Manangement increased its TG Therapeutics (TGTX) stake by 7.5% in Q2 2026, buying an estimated $43.8K and bringing the position to 15,378 shares worth $908K. The position accounts for 0.02% of the portfolio, ranked #400.

NorthCrest Asset Manangement first reported a position in TGTX in Q4 2024 and has held it in 7 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

NorthCrest Asset Manangement held 15,378 shares of TG Therapeutics worth $908K as of Q2 2026.
NorthCrest Asset Manangement bought 1,071 TG Therapeutics shares in Q2 2026, an estimated $43.8K.
TG Therapeutics made up 0.02% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #400 holding.
NorthCrest Asset Manangement first reported a position in TG Therapeutics in Q4 2024 and has held it in 7 quarters since.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.